Merck Foresees Addition By Subtraction For Rx Statins If Mevacor Goes OTC
This article was originally published in The Tan Sheet
Executive Summary
Merck says Mevacor OTC will be a net positive for the company's prescription statin business
You may also be interested in...
Pravachol OTC Deal Reached Between Bayer, Bristol
Bayer is following through on its aim to become the preeminent switch player through a deal with Bristol-Myers Squibb for OTC Pravachol in the U.S
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands